Targeting AKR1B1 reprograms tumor-associated macrophages to enhance antitumor immunity.

J Immunother Cancer · 2026 · PMC12853464 · PMID 41592892

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

Clinically, high AKR1B1 expression was significantly associated with poor survival in patients with TNBC, while a strong trend toward inferior survival was also observed in patients with LUAD ( figure 7N ).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.